Aryl hydrocarbon receptor as a drug target in advanced prostate cancer therapy obstacles and perspectives
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F24%3A00603284" target="_blank" >RIV/68081707:_____/24:00603284 - isvavai.cz</a>
Result on the web
<a href="https://www.tandfonline.com/doi/full/10.1080/21541264.2024.2334106" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/21541264.2024.2334106</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/21541264.2024.2334106" target="_blank" >10.1080/21541264.2024.2334106</a>
Alternative languages
Result language
angličtina
Original language name
Aryl hydrocarbon receptor as a drug target in advanced prostate cancer therapy obstacles and perspectives
Original language description
Aryl hydrocarbon receptor (AhR) is a transcription factor that is primarily known as an intracellular sensor of environmental pollution. After five decades, the list of synthetic and toxic chemicals that activate AhR signaling has been extended to include a number of endogenous compounds produced by various types of cells via their metabolic activity. AhR signaling is active from the very beginning of embryonal development throughout the life cycle and participates in numerous biological processes such as control of cell proliferation and differentiation, metabolism of aromatic compounds of endogenous and exogenous origin, tissue regeneration and stratification, immune system development and polarization, control of stemness potential, and homeostasis maintenance. AhR signaling can be affected by various pharmaceuticals that may help modulate abnormal AhR signaling and drive pathological states. Given their role in immune system development and regulation, AhR antagonistic ligands are attractive candidates for immunotherapy of disease states such as advanced prostate cancer, where an aberrant immune microenvironment contributes to cancer progression and needs to be reeducated. Advanced stages of prostate cancer are therapeutically challenging and characterized by decreased overall survival (OS) due to the metastatic burden. Therefore, this review addresses the role of AhR signaling in the development and progression of prostate cancer and discusses the potential of AhR as a drug target for the treatment of advanced prostate cancer upon entering the phase of drug resistance and failure of first-line androgen deprivation therapy.Abbreviation: ADC: antibody-drug conjugate, ADT: androgen deprivation therapy, AhR: aryl hydrocarbon receptor, AR: androgen receptor, ARE: androgen response element, ARPI: androgen receptor pathway inhibitor, mCRPC: metastatic castration-resistant prostate cancer, DHT: 5a-dihydrotestosterone, FICZ: 6-formylindolo[3,2-b]carbazole, 3-MC: 3-methylcholanthrene, 6-MCDF: 6-methyl-1,3,8-trichlorodibenzofuran, MDSCs: myeloid-derived suppressor cells, PAHs: polycyclic aromatic hydrocarbons, PCa: prostate cancer, TAMs: tumor-associated macrophages, TF: transcription factor, TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin, TME: tumor microenvironment, TRAMP: transgenic adenocarcinoma of the mouse prostate, TROP2: tumor associated calcium signal transducer 2
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
<a href="/en/project/GA21-11585S" target="_blank" >GA21-11585S: Dynamics of cancer cell surface fingerprint plasticity in epithelial-to-mesenchymal transition</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Transcription-Austin
ISSN
2154-1264
e-ISSN
2154-1272
Volume of the periodical
„neuveden“
Issue of the periodical within the volume
„neuveden“
Country of publishing house
US - UNITED STATES
Number of pages
20
Pages from-to
—
UT code for WoS article
001194216100001
EID of the result in the Scopus database
2-s2.0-85189646965